New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:21 EDTMNTA, ACTG, NEM, SRPT, MU, CBEY, AMD, NUS, PFE, TEVA, ATHN, ABX, RNA, AZNOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.
News For AZN;PFE;SRPT;RNA;NUS;NEM;ABX;AMD;ACTG;ATHN;CBEY;MNTA;TEVA;MU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
April 21, 2015
08:50 EDTTEVATeva sees Mylan deal yielding non-GAAP EPS accretion in mid-teens in first year
Subscribe for More Information
08:48 EDTTEVATeva expects proposed Mylan deal could be completed by year-end 2015
Subscribe for More Information
08:47 EDTTEVAMylan jumps 8% to $73.50 after Teva proposes $82 per share takeover bid
08:46 EDTTEVATeva offers to acquire Mylan for $82.00 per share in cash and stock
Teva Pharmaceutical Industries (TEVA) announced a proposal to acquire all of the outstanding shares of Mylan N.V. (MYL) in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company. Teva’s proposal also provides Mylan stockholders with a more attractive alternative to Mylan’s proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Teva’s proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan’s press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. The proposed combination of Teva and Mylan would create a leading company in the pharmaceutical industry, well positioned to transform the global generics space. The combined company would leverage its significantly more efficient and advanced infrastructure, with enhanced scale, production network, end-to-end product portfolio, commercialization capabilities and geographic reach. With this platform, the combined company would focus on complex technologies and more durable and sustainable products, in combination with robust capabilities in specialty drug development and commercialization. As a result, the combined company would have a unique and differentiated business model addressing significant trends and discontinuities prevailing today among patients and healthcare systems around the world. The combined company would also have an enhanced financial profile, creating the opportunity for rapid deleveraging and the funding of future growth – in generics, specialty and the intersection of the two.
08:45 EDTTEVATeva offers to acquire Mylan for $82.00 per share in cash and stock
Subscribe for More Information
08:41 EDTTEVAOptions expected to be active
Options expected to be active: UA TEVA PRGO MYL UTX QCOM VMW HOG CMG IBM VZ
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
07:11 EDTMUMicron does not have negative read through from Lam results, says RBC Capital
RBC Capital says that Lam Research's (LRCX) beat and raise results do not increase its concern about oversupply in the memory market. RBC believes that the results indicate a market share shift, not an increase in aggregate DRAM spending. RBC says that DRAM prices are stable, and it keeps an Outperform rating on Micron (MU).
07:06 EDTAZNBina Tech, AstraZeneca announce collaborative agreement for GMS
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
06:01 EDTTEVATeva bid for Mylan could come today, Bloomberg reports
Subscribe for More Information
April 20, 2015
17:33 EDTABXBarrick Gold pursues sale of Zaldivar mine, Reuters says
Barrick Gold has contacted a small group of buyers regarding a potential sale of its Zaldivar copper mine, Reuters reported earlier, citing three sources familiar with the matter. The sources said a deal could be worth roughly $2B, and added that Barrick is likely to retain a stake in the mine rather than pursue a full sale. Reference Link
13:24 EDTABXNewcrest, Hecla, Gold Fields bid for Barrick mine, WSJ says
Newcrest (NCMGY), Hecla (HL), Gold Fields (GFI), and Evolution Mining have advanced to the second round of bidding for Barrick Gold's (ABX) Cowal mine in Australia, reports the Wall Street Journal, citing two sources familiar with the matter. One of the sources noted that the mine could be worth as much as $700M. Reference Link
12:52 EDTABXBarrick Australian mine bid on by Hecla, Newcrest Mining, DJ says
Subscribe for More Information
11:40 EDTTEVATeva may pay $512M to settle claims of delaying generic Provigil, Reuters says
Subscribe for More Information
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
07:18 EDTMNTAAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
06:39 EDTTEVACiti believes Teva, Mylan deal would have to be friendly
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
06:02 EDTAZNClovis pullback on Astra data a buying opportunity, says Mizuho
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use